Author

Ram Kannan

Memorial Sloan Kettering Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Approach:deep learning· 1

Frequent Co-Authors

A.M. EdwardsiD· 1 shared Albina Bolotokova· 1 shared Alexander Edward Dela Cruz DriloniD· 1 shared C.H. ArrowsmithiD· 1 shared Conrad Veranso SimobeniD· 1 shared Corina AmoriD· 1 shared Derek J. WilsoniD· 1 shared Douglas Warner· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A.M. EdwardsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification and Characterization of a Small Molecule Ligand for the Huntingtin-HAP40 Complex

Rocher Leung, Esther Wolf, Justin C. Deme, Swati Balakrishnan, Conrad Veranso Simoben, Shulu Feng, Jonathan D. Macdonald, Renu Chandrasekaran, Jianxian Sun, Xiaoyun Wang, Albina Bolotokova, Yefen Zou, Ram Kannan, Suzanne Z. Ackloo, Derek J. Wilson, , Rachel Harding

The paper identifies a small molecule ligand for the HTT-HAP40 complex using AS-MS and validates its binding through multiple techniques, highlighting a druggable interface for HD therapeutics.

bioRxiv · Nov 21, 2025 · PreprintPharmacology & Toxicology

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Jacob A. Boyer, Ezra Y. Rosen, Malvika Sharma, Madeline A. Dorso, Nicholas Mai, Corina Amor, Jason Reiter, Ram Kannan, Sunyana Gadal, Jianing Xu, Matthew M. Miele, Zhuoning Li, Xiaoping Chen, Qing Chang, Fresia G. Pareja, , Neal X. Rosen

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

Proceedings of the National Academy of Sciences · Jul 21, 2025Peer-reviewedCancer Biology